Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Détails

ID Serval
serval:BIB_24074
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Périodique
Journal of Clinical Oncology
Auteur(s)
Keating M.J., Cazin B., Coutré S., Birhiray R., Kovacsovics T., Langer W., Leber B., Maughan T., Rai K., Tjønnfjord G., Bekradda M., Itzhaki M., Hérait P.
ISSN
0732-183X
Statut éditorial
Publié
Date de publication
2002
Volume
20
Numéro
1
Pages
205-213
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Résumé
PURPOSE: We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic leukemia (T-PLL) patients in a compassionate-use program. PATIENTS AND METHODS: Seventy-six patients with T-PLL (including four chemotherapy-naive patients) received 3, 10, and 30 mg of Campath-1H on sequential days, followed by 30 mg three times weekly, as 2-hour intravenous infusions, for 4 to 12 weeks. RESULTS: Median patient age was 60 years (range, 35 to 84). Spleen liver, lymph node, and skin involvement were present in 64%, 40%, 54%, and 18% of patients, respectively. All tested patients had CD2, CD7, CD4, and/or CD8 positivity, whereas CD5 and CD3 were positive in 98% and 96% of tested patients, respectively. The objective response rate was 51% (95% confidence interval [CI], 40% to 63%), with a 39.5% complete response (CR) rate (95% CI, 28% to 51%). The median duration of CR was 8.7 months (range, 0.13+ to 44.4), and median time to progression was 4.5 months (range, 0.1 to 45.4) compared with 2.3 months (range, 0.2 to 28.1) after first-line chemotherapy. The median overall survival was 7.5 months (14.8 months for CR patients). The most common Campath-1H-related adverse events were acute reactions during or immediately after infusions. Fifteen infectious episodes occurred during treatment in 10 patients (13%), leading to treatment discontinuation in three. Eight patients experienced possibly related, late-onset infections. Severe thrombocytopenia and/or neutropenia occurred in six patients (8%), leading to treatment discontinuation in four. Two treatment-related deaths occurred. CONCLUSION: Campath-1H is an active drug in T-PLL patients for whom first-line therapy has failed. It has a favorable risk/benefit ratio and should be prospectively investigated in chemotherapy-naive patients.
Mots-clé
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Antibodies, Neoplasm/adverse effects, Antibodies, Neoplasm/therapeutic use, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Consumer Product Safety, Female, Hematologic Diseases/chemically induced, Hematologic Diseases/epidemiology, Humans, Infusions, Intravenous, Leukemia, T-Cell/drug therapy, Leukemia, T-Cell/mortality, Male, Middle Aged, Opportunistic Infections/chemically induced, Opportunistic Infections/epidemiology, Retrospective Studies, Salvage Therapy/methods, Survival Rate, Time Factors
Pubmed
Web of science
Création de la notice
19/11/2007 13:20
Dernière modification de la notice
03/03/2018 14:56
Données d'usage